Celldex Therapeutics (CLDX) Research & Development (2010 - 2026)

Celldex Therapeutics' Research & Development history runs 17 years deep, the most recent figure standing at $73.0 million for Q1 2026.

• In Q1 2026, Research & Development rose 38.75% year-over-year to $73.0 million; the TTM figure through Mar 2026 stood at $265.5 million (up 43.88% YoY), while the FY2025 annual figure was $245.1 million, up 49.85% from the prior year.
• Research & Development was $73.0 million for Q1 2026 at Celldex Therapeutics, down from $75.3 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $75.3 million in Q4 2025 to a low of $17.1 million in Q1 2022.
• Historically, Research & Development has averaged $40.1 million across 5 years, with a median of $34.5 million in 2023.
• The sharpest annual moves came in 2022 and 2024: Research & Development soared 67.78% in 2022, then rose 18.15% in 2024.
• A 5-year view of Research & Development shows it stood at $22.9 million in 2022, then soared by 32.87% to $30.4 million in 2023, then soared by 54.27% to $46.9 million in 2024, then jumped by 60.49% to $75.3 million in 2025, then declined by 3.1% to $73.0 million in 2026.
• The last three Research & Development figures came in at $73.0 million (Q1 2026), $75.3 million (Q4 2025), and $62.9 million (Q3 2025), per Business Quant data.